



Table S1. Composition of the aqueous extract of pepino leaf (AEPL).

Polyphenolic compound	AEPL ^a (%)
Total phenolic acid (Folin-Ciocalteu method b)	5.52 ± 1.27
Total flavonoids (Jia method ^c)	25.32 ± 0.48
Total anthocyanins (Fuleki and Francis method ^d)	2.02 ± 1.13

^a The AEPL was prepared as described in Materials and Methods. ^{b-d} The concentrations of total phenolic accid, flavonoid, and anthocyanin were analyzed according to the Folin-Ciocalteau method [Lakenbrink et al., 2000], Jia method [Jia et al., 1998], Fuleki and Francis method [Fuleki and Francis, 1968], receptively.

Table S2. Composition of the aqueous extract of pepino leaf (AEPL) vs. pepino fruits.

Polyphenolic compounds (mg/100g dry weight)	AEPL ^a	PAE ^b
Total phenolic acid (Folin-Ciocalteu method ^c)	933 ± 228	1217 ± 188
Total flavonoids (Jia method d)	4550 ± 86	875 ± 62
Total anthocyanins (Fuleki and Francis method ^e)	360 ± 203	177 ± 51

a The AEPL was prepared as described in Materials and Methods.b The composition of aqueous extract of pepino fruit (PAE) was cited by the study of Hsu, Guo et al.c-e The concentrations of total phenolic acid, flavonoid, and anthocyanin were analyzed according to the Folin-Ciocalteau method (Lakenbrink et al., 2000), Jia method (Jia et al., 1998), Fuleki and Francis method (Fuleki and Francis, 1968), receptively.

Nutrients **2018**, 10, 931

 Table S3. Comparison of various plant-derived polyphenols.

		AEPL	HSE	GTE
Full name		aqueous extract of pepino leaf	aqueous extracts from Hibiscus sabdariffa	Green tea extract
Component		phenolic acids, flavonoids, anthocyanins,	phenolic acids, flavonoids, anthocyanins	EGCG, EGC, ECG, EC, caffeine
Major compound (%)		N/A a	N/A	EGCG (30-42%)
Anti-cancer and oxidative DNA damage	Animal models	N/A	1-2% (ICR mice)	2% (A/J mice)
	Human studies	N/A	N/A	3 g/day; 10%
Anti-lipid peroxidation and atherosclerosis	Animal models	N/A	0.5% –1% (New Zealand White rabbits)	50 mg/kg; 3% (Wistar rats)
	Human studies	N/A	1 g/day	600 mg/day
Hypoglycemic	Animal models	N/A	200 mg/kg (SD rats)	500 mg/kg (SD rats)
	Human studies	N/A	2 g/day	857 mg/day
Hepatoprotection	Animal models	1–2% (C57BL/6J mice)	1–5% (Wistar rats); 200–600 mg/kg (BALB/c mice)	2.5% (Wistar rats)
	Human studies	N/A	N/A	N/A
Referenc	ce	In our manuscript, 2017	Chen et al., 2005; Lin et al., 2007; Liu et al., 2006; Liu et al., 2010; Mozaffari- Khosravi et al., 2008; Pheng et al., 2011	Higdon & Frei, 2003; Hsu et al., 2011; Kuzu et al., 2008; Lin et al., 1998; Li, Sun, Han, & Chen, 1999; Miura et al., 2000; Sano etal., 1995; Xu et al., 1992

N/A, Not available.